|
1
|
Gao X, Fisher SG and Emami B: Risk of
second initial cancer in the contralateral breast in women treated
for early-stage breast cancer: A population-based study. Int J
Radiat Oncol Biol Phys. 56:1038–1045. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jobsen JJ, van der Palen J, Ong F,
Riemersma S and Struikmans H: Bilateral breast cancer, synchronous
and metachronous; differences and outcome. Breast Cancer Res Treat.
153:277–283. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Klevebring D, Lindberg J, Rockberg J,
Hilliges C, Hall P, Sandberg M and Czene K: Exome sequencing of
contralateral breast cancer identifies metastatic disease. Breast
Cancer Res Treat. 151:319–324. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Begg CB, Ostrovnaya I, Geyer FC,
Papanastasiou AD, Ng CKY, Sakr RA, Bernstein JL, Burke KA, King TA,
Piscuoglio S, et al: Contralateral breast cancers: Independent
cancers or metastases? Int J Cancer. 142:347–356. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schaapveld M, Visser O, Louwman WJ,
Willemse PH, de Vries EG, van der Graaf WT, Otter R, Coebergh JW
and van Leeuwen FE: The impact of adjuvant therapy on contralateral
breast cancer risk and the prognostic significance of contralateral
breast cancer: A population based study in the Netherlands. Breast
Cancer Res Treat. 110:189–197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miller TW, Balko JM and Arteaga CL:
Phosphatidylinositol 3-kinase and antiestrogen resistance in breast
cancer. J Clin Oncol. 29:4452–4461. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shou J, Massarweh S, Osborne CK, Wakeling
AE, Ali S, Weiss H and Schiff R: Mechanisms of tamoxifen
resistance: Increased estrogen receptor-HER2/neu cross-talk in
ER/HER2-positive breast cancer. J Natl Cancer Inst. 96:926–935.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Al Saleh S, Sharaf LH and Luqmani YA:
Signalling pathways involved in endocrine resistance in breast
cancer and associations with epithelial to mesenchymal transition
(Review). Int J Oncol. 38:1197–1217. 2011.PubMed/NCBI
|
|
9
|
Yanai A, Inoue N, Yagi T, Nishimukai A,
Miyagawa Y, Murase K, Imamura M, Enomoto Y, Takatsuka Y, Watanabe
T, et al: Activation of mTOR/S6K but not MAPK pathways might be
associated with High Ki-67, ER+, and HER2 breast cancer.
Clin Breast Cancer. 15:197–203. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun CH, Chang YH and Pan CC: Activation of
the PI3K/Akt/mTOR pathway correlates with tumour progression and
reduced survival in patients with urothelial carcinoma of the
urinary bladder. Histopathology. 58:1054–1063. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fingar DC, Richardson CJ, Tee AR, Cheatham
L, Tsou C and Blenis J: mTOR controls cell cycle progression
through its cell growth effectors S6K1 and 4E-BP1/eukaryotic
translation initiation factor 4E. Mol Cell Biol. 24:200–216. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mamane Y, Petroulakis E, LeBacquer O and
Sonenberg N: mTOR, translation initiation and cancer. Oncogene.
25:6416–6422. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bose S, Chandran S, Mirocha JM and Bose N:
The Akt pathway in human breast cancer: A tissue-array-based
analysis. Mod Pathol. 19:238–245. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song CH, Park SY, Eom KY, Kim JH, Kim SW,
Kim JS and Kim IA: Potential prognostic value of heat-shock protein
90 in the presence of phosphatidylinositol-3-kinase overexpression
or loss of PTEN, in invasive breast cancers. Breast Cancer Res.
12:R202010. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brewster AM and Parker PA: Current
knowledge on contralateral prophylactic mastectomy among women with
sporadic breast cancer. Oncologist. 16:935–941. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Z, Yun R, Yu X, Hu H, Huang G, Tan B
and Chen T: Overexpression of Notch3 and pS6 is associated with
poor prognosis in human ovarian epithelial cancer. Mediators
Inflamm. 2016:59534982016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Polo ML, Riggio M, May M, Rodríguez MJ,
Perrone MC, Stallings-Mann M, Kaen D, Frost F, Goetz M, Boughey J,
et al: Activation of PI3K/Akt/mTOR signaling in the tumor stroma
drives endocrine therapy-dependent breast tumor regression.
Oncotarget. 6:22081–22097. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Beelen K, Hoefnagel LD, Opdam M, Wesseling
J, Sanders J, Vincent AD, van Diest PJ and Linn SC: PI3K/AKT/mTOR
pathway activation in initial and corresponding metastatic breast
tumors after adjuvant endocrine therapy. Int J Cancer.
135:1257–1263. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim EK, Kim HA, Koh JS, Kim MS, Kim KI,
Lee JI, Moon NM, Ko E and Noh WC: Phosphorylated S6K1 is a possible
marker for endocrine therapy resistance in hormone
receptor-positive breast cancer. Breast Cancer Res Treat.
126:93–99. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ray S and Darbre PD: Crosstalk with
insulin and dependence on PI3K/Akt/mTOR rather than MAPK pathways
in upregulation of basal growth following long-term oestrogen
deprivation in three human breast cancer cell lines. Horm Mol Biol
Clin Investig. 5:53–65. 2011.PubMed/NCBI
|
|
22
|
Martin LA, Farmer I, Johnston SR, Ali S,
Marshall C and Dowsett M: Enhanced estrogen receptor (ER) alpha,
ERBB2, and MAPK signal transduction pathways operate during the
adaptation of MCF-7 cells to long term estrogen deprivation. J Biol
Chem. 278:30458–30468. 2003. View Article : Google Scholar : PubMed/NCBI
|
